March 8, 2017
Webinar
The U.S. Food and Drug Administration (FDA) recently issued a Final Rule implementing provisions of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also known as the Medicare Modernization Act (MMA). According to the FDA, provisions of the Final Rule also serve “to clarify and update [FDA] regulations based on recent court decisions and [the FDA’s] practical experience.”
This new rule is expected to impact multiple players in the pharmaceutical industry leading up to and during Hatch-Waxman litigation between innovators and generic companies.
This webinar will provide an overview of the new rule and will focus on key aspects of the rule and assess their potential impact on Hatch-Waxman litigants. Topics will include:
This webinar is the third and final segment of Finnegan’s Winter 2017 series, “The Evolving IP Landscape in the United States: Challenges & Opportunities.”
Speakers:
Paul W. Browning, Ph.D.
Denise Main, Ph.D.
Wednesday, March 8, 2017
7:30 - 8:30 a.m. India
10:00 - 11:00 a.m. China/Taiwan
11:00 a.m. - 12:00 p.m. Japan/Korea
Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.